Use of pharmacokinetic-pharmacodynamic modeling with Monte Carlo simulation to reduce antibiotic expenditures without compromising predicted efficacy

被引：0

|

作者：

Frei, CR

Lewis, JS

Burgess, DS

机构：

[1] Univ Texas, Austin, TX 78712 USA

[2] Univ Texas, Hlth Sci Ctr, San Antonio, TX USA

[3] Univ Hlth Syst, San Antonio, TX USA

来源：

VALUE IN HEALTH | 2006年 / 9卷 / 03期

关键词：

D O I：

10.1016/S1098-3015(10)64798-5

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

收藏

页码：A160 / A160

页数：1

相关论文

共 23 条

[21] The use of Beowulf cluster to accelerate the performance of Monte-Carlo parametric expectation maximization (MCPEM) algorithm in analyzing complex population pharmacokinetic/pharmacodynamic/efficacy data.
Ng, CM
Bauer, RJ
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P54 - P54
[22] Use of Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling and Simulations to Predict Efficacy Outcomes with Eslicarbazepine Acetate (ESL) 800mg Once-Daily (QD) as Monotherapy
Sunkaraneni, Soujanya
Passarell, Julie
Pitner, Janet
Grinnell, Todd
Blum, David
[J]. NEUROLOGY, 2016, 86
[23] Appropriate use of triazolam in elderly patients considering a quantitative benefit-risk assessment based on the pharmacokinetic-pharmacodynamic modeling and simulation approach supported by real-world data
Okada, Akira
Sera, Shoji
Nagai, Naomi
[J]. BMC PHARMACOLOGY & TOXICOLOGY, 2024, 25 (01):